Medical/Pharmaceuticals News & Press Release Distribution

Medical/Pharmaceuticals

APAC
Global

I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer

SHANGHAI and GAITHERSBURG, Md., March 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the U.S. Food and Drug Administration (FDA) has gr...

2022-03-03 21:00 1675

CNN's Vital Signs explores the future of medicine

HONG KONG, March 3, 2022 /PRNewswire/ -- From personalized vaccines to lab-grown organs and AI-powered medical devices, the future of medicine is happening right now in labs across the world. This month on CNN's 'Vital Signs' , Chief Medical Correspondent Dr. Sanjay Gupta ...

2022-03-03 10:13 2952

CNN's Vital Signs explores the future of medicine

Sequential Skin debuts Sequential Bio - the world's first in-vivo microbiome testing solution for skin, hair, and personal product industries.

LONDON, NEW YORK and SINGAPORE, March 3, 2022 /PRNewswire/ -- Sequential Skin Ltd, a leading microbiome company today announced the debut ofSequential Bio – a novel "in-vivo" microbiome testing solution uniquely tailored for companies across skincare, haircare, and p...

2022-03-03 07:55 2012

Sequential Skin debuts Sequential Bio - the world's first in-vivo microbiome testing solution for skin, hair, and personal product industries.

Akeso Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evaluate Cadonilimab in Combination with Chiauranib for Extensive-Stage Small-Cell Lung Cancer

HONG KONG, March 2, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwidetoday announced that it has entered into a collab...

2022-03-03 01:34 1954

Zhongshan Chenxinghai Hospital, Hong Kong Integrated Oncology Centre and healthcare distributor DCH Auriga partner to provide Hong Kong-approved medical treatments to GBA patients

HONG KONG, March 2, 2022 /PRNewswire/ -- On 2 March 2022, Zhongshan Chenxinghai Hospital,a leading Hong Kong cancer treatment centre, Hong Kong Integrated Oncology Centre ("HKIOC"), and healthcare distributor DCH Auriga announced their strategic cooperation in support of a National State Council ...

2022-03-02 20:02 3178

Seegene appoints Richard Creager as CEO of U.S. subsidiary to bolster U.S. business

SEOUL, South Korea, March 2, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today announced the appointment ofRichard S. Creager, Ph.D., as the CEO of itsUnited States subsidiary, Seegene Technologies

2022-03-02 20:00 1334

Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates

SAN DIEGO and SUZHOU, China, Mar. 2, 2022 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced a collaboration and exclusive license agreement with Sanofi to generate masked monoclonal and bispe...

2022-03-02 19:00 2761

Intellect offers free access to healthcare workers to support mental well-being during surge in healthcare demand

SINGAPORE, March 2, 2022 /PR Newswire/ -- Singapore-based mental health platformIntellect is providing three-month premium access to healthcare workers inSingapore at no cost, aiming to help maintain their mental well-being. The self-care app company recognizes the impo...

2022-03-02 17:56 2652

REDCLOUD BIO ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR NEXT-GENERATION EGFR INHIBITOR H002 IN NON-SMALL CELL LUNG CANCER

* Drug Candidate Is First From Company To Enter Phase I/IIa Clinical Trial * H002 Has Potential To Overcome Resistance Driven By Various EGFR C797S-Containing Mutations in Non-Small Cell Lung Cancer SHANGHAI, March 2, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an innovative biotech com...

2022-03-02 17:27 1071

InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China

BEIJING, March 1, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National Medical Products Administration (NMPA) to start ph...

2022-03-02 10:37 1778

WuXi Biologics Wins CMO Leadership Awards in All Six Core Categories for Fifth Consecutive Year

SHANGHAI, March 1, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, today announced that the company has won the 2022 CMO Leadership Awards in all six core categories (i.e., capabilities, compatibility, expertise, reliability, quality and service).2022 m...

2022-03-02 10:07 1729

Malaysian-Made ProDetect(R) Rapid Test-Kit Scores 100% Accuracy in International Assessment

GEORGE TOWN, Malaysia, March 2, 2022 /PRNewswire/ -- As the Omicron variant takes hold inMalaysia, the availability of high accuracy Antigen Test Kits is increasingly vital in the drive to identify infection early on and prevent further spread in the community. The ProDetect® COVID-19 Antigen Rap...

2022-03-02 09:15 2359

Malaysian-Made ProDetect(R) Rapid Test-Kit Scores 100% Accuracy in International Assessment

ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China

SHENZHEN, China, March 1, 2022 /PRNewswire/ -- Following its robust safety data in the U.S. Phase I clinical study, ImmVira announced that its global first intravenous administered oncolytic herpes simplex virus ("oHSV") product MVR-T3011 IV has completed first dosing onMarch 1, 2022 and initiate...

2022-03-02 09:07 1072

ImmVira's breakthrough intravenous oncolytic virus product MVR-T3011 IV completed first dosing in Phase I clinical trial in China

Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications

SHANGHAI and HONG KONG, March 2, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer and other life...

2022-03-02 08:47 2432

Amrita University launch wearable device for home monitoring of glucose and BP

- Patients can use the wearable, non-invasive device to measure six body parameters including blood glucose, blood pressure, heart rate, blood oxygen, respiratory rate and 6-lead ECG, from the comfort of their home - The device, connected to the smart phone, can serve as a micro-bedside monitor ...

2022-03-02 07:40 1994

Amrita University launch wearable device for home monitoring of glucose and BP

The Sigourney Trust Issues Call For Entries Of Psychoanalytic Work Eligible To Win The Sigourney Award-2022

Applications For The Sigourney Award-2022 Accepted March 1 Through July 31 SEATTLE, March 1, 2022 /PRNewswire/ -- Each year The Sigourney Trust honors up to four individuals, groups or organizations with an independent prize,The Sigourney Award. This prestigious international award honors recent...

2022-03-01 22:15 1558

Cambrex Expands Biopharmaceutical Services Business

EAST RUTHERFORD, N.J., March 1, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced it is significantly expanding its existing b...

2022-03-01 22:00 2237

Vocera, now part of Stryker, introduces latest evolution in hands-free communication to help protect and connect healthcare workers

New Minibadge expands intuitive mobile solutions for care team collaboration and safety KALAMAZOO, Michigan, USA, March 1, 2022 /PRNewswire/ -- Vocera, now part of Stryker, a global leading medical technology company, introduced the new Minibadge, a wearable, voice-driven device that enables mobi...

2022-03-01 21:00 1204

Kintor Pharma Announces First Patient Dosing in Phase II Clinical Trial of KX-826 for Treatment of Androgenic Alopecia Patients in the US

SUZHOU, China, March 1, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826 ("...

2022-03-01 20:30 1658

Rare Disease Day | With iCare, Love is Not Rare, MediTrust Health - iCare Clover Gives Care and Protection to Rare Disease Patients

SHANGHAI, March 1, 2022 /PRNewswire/ -- "When Zixu was about 10 months old, he already seemed different from other children. He has curved fingers, a gradually bulging belly, and his intelligence also grows slowly," Zixu's mother calmly recounted the process of taking her child to seek medical tr...

2022-03-01 20:05 1356

1 ... 276 277 278279280 281 282 ... 577